Badrian M, Bazrafkan L, Shakour M
BMC Psychol. 2022; 10(1):187.
PMID: 35906665
PMC: 9336078.
DOI: 10.1186/s40359-022-00896-4.
Gautam C, Sharma J, Singla M, Tiwana I, Singh H
touchREV Endocrinol. 2022; 17(1):33-36.
PMID: 35118444
PMC: 8320008.
DOI: 10.17925/EE.2021.17.1.33.
Karahmadi M, Saadatmand S, Javad Tarahi M
Adv Biomed Res. 2020; 9:18.
PMID: 32695728
PMC: 7365383.
DOI: 10.4103/abr.abr_9_20.
Iqbal M, Levin C, Levin F
Focus (Am Psychiatr Publ). 2020; 17(2):88-97.
PMID: 31975963
PMC: 6526999.
DOI: 10.1176/appi.focus.20180042.
Pary R, Scarff J, Jijakli A, Tobias C, Lippmann S
Fed Pract. 2019; 32(Suppl 3):30S-37S.
PMID: 30766117
PMC: 6375494.
Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway.
Motaghinejad M, Motevalian M, Falak R, Heidari M, Sharzad M, Kalantari E
J Neural Transm (Vienna). 2016; 123(12):1463-1477.
PMID: 27665547
DOI: 10.1007/s00702-016-1619-1.
Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants.
Weyandt L, Oster D, Marraccini M, Gudmundsdottir B, Munro B, Zavras B
Psychol Res Behav Manag. 2014; 7:223-49.
PMID: 25228824
PMC: 4164338.
DOI: 10.2147/PRBM.S47013.
An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults.
Kollins S, Schoenfelder E, English J, Holdaway A, Van Voorhees E, OBrien B
J Subst Abuse Treat. 2014; 48(1):96-103.
PMID: 25175495
PMC: 4250392.
DOI: 10.1016/j.jsat.2014.07.014.
Environmental enrichment preceding early adulthood methylphenidate treatment leads to long term increase of corticosterone and testosterone in the rat.
Avital A, Dolev T, Aga-Mizrachi S, Zubedat S
PLoS One. 2011; 6(7):e22059.
PMID: 21789212
PMC: 3137618.
DOI: 10.1371/journal.pone.0022059.
Short-acting versus Long-acting Medications for the Treatment of ADHD.
Cascade E, Kalali A, Weisler R
Psychiatry (Edgmont). 2009; 5(8):24-7.
PMID: 19727272
PMC: 2695738.
Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician.
Upadhyaya H
Prim Care Companion J Clin Psychiatry. 2008; 10(3):211-21.
PMID: 18615170
PMC: 2446489.
DOI: 10.4088/pcc.v10n0306.
Nonmedical use of prescription stimulants among college students: associations with attention-deficit-hyperactivity disorder and polydrug use.
Arria A, Caldeira K, OGrady K, Vincent K, Johnson E, Wish E
Pharmacotherapy. 2008; 28(2):156-69.
PMID: 18225963
PMC: 2906759.
DOI: 10.1592/phco.28.2.156.
Treatment strategies for co-occurring ADHD and substance use disorders.
Mariani J, Levin F
Am J Addict. 2007; 16 Suppl 1:45-54.
PMID: 17453606
PMC: 2676785.
DOI: 10.1080/10550490601082783.
Prevalence of methylphenidate use among Israeli children: 1998-2004.
Vinker S, Vinker R, Elhayany A
Clin Drug Investig. 2006; 26(3):161-7.
PMID: 17163247
DOI: 10.2165/00044011-200626030-00006.
Nonmedical use of prescription stimulants among students.
Arria A, Wish E
Pediatr Ann. 2006; 35(8):565-71.
PMID: 16986451
PMC: 3168781.
DOI: 10.3928/0090-4481-20060801-09.
Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: patterns, user characteristics, and management options.
Smith M, Woody G
Curr Psychiatry Rep. 2005; 7(5):337-43.
PMID: 16216151
DOI: 10.1007/s11920-005-0033-4.